(NASDAQ: ACAD) Acadia Pharmaceuticals's forecast annual revenue growth rate of 10.8% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 31.63%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 12.01%.
Acadia Pharmaceuticals's revenue in 2026 is $1,202,301,000.On average, 23 Wall Street analysts forecast ACAD's revenue for 2026 to be $225,887,466,404, with the lowest ACAD revenue forecast at $215,690,557,056, and the highest ACAD revenue forecast at $234,356,086,032. On average, 23 Wall Street analysts forecast ACAD's revenue for 2027 to be $255,095,562,672, with the lowest ACAD revenue forecast at $230,208,190,704, and the highest ACAD revenue forecast at $276,180,697,256.
In 2028, ACAD is forecast to generate $282,229,711,276 in revenue, with the lowest revenue forecast at $254,749,904,728 and the highest revenue forecast at $313,684,584,180.